BCRX vs REGN · rev $374.7M vs P/E 14, rev $4.29B
BioCryst Pharmaceuticals Inc (BCRX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
BioCryst Pharmaceuticals Inc (BCRX) is a drug manufacturers - specialty & generic company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BCRX revenue for 2026-06-30 was $374.7M. Net income was -$643.4M. BCRX currently screens at market cap $1.83B.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BCRX currently screens at market cap $1.83B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BCRX and REGN stock pages for the full models.
Not investment advice.